ClinicalTrials.gg

Program

TJ0113

A development code. Also written as “TJ0113 200mg”, “TJ0113 400mg” and “TJ0113 Capsules”.

Its studies are mostly in Depression · Parkinson Disease · Sarcopenia, led by Hangzhou PhecdaMed.

Furthest: phase 3, since Jul 28, 20265 company-led studies, 2 open or runningNext primary completion: Aug 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou PhecdaMed52 open or runningphase 3since Jul 28, 2026Feb 6, 2025Aug 22, 2027phase 2 · NCT07620938

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2025First study: phase 1 study in Healthy Chinese SubjectsFirst studyNCT06832540 · 6 enrolled · China
  2. Jun 4, 2025Phase 2 study in DepressionNCT07018245 · 149 enrolled · China
  3. Jan 26, 2026Phase 1 study in Healthy SubjectsNCT07394452 · 130 enrolled · China
  4. May 27, 2026Phase 2 study in SarcopeniaNCT07620938 · 204 planned · China
  5. Jul 28, 2026Phase 3 study in Parkinson DiseasePhase 3 reachedNCT07741045 · 300 planned · China

Ahead

  1. Aug 22, 2027Primary completion: phase 2 study in SarcopeniaNCT07620938
  2. Jan 15, 2028Primary completion: phase 3 study in Parkinson DiseaseNCT07741045

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07741045Parkinson Disease · China3Not yet recruitingJan 15, 2028300
NCT07620938Sarcopenia · China2RecruitingAug 22, 2027204
NCT07394452Healthy Subjects · China1CompletedFeb 5, 2024130
NCT07018245Depression · China2CompletedJun 25, 2026149
NCT06832540Healthy Chinese Subjects · China1CompletedMar 5, 20256

How it is read

Names in the registry

  • “TJ0113”, 4 entries
  • “TJ0113 200mg”, 1 entry
  • “TJ0113 400mg”, 1 entry
  • “TJ0113 Capsules”, 1 entry
  • “[14C]TJ0113”, 1 entry

Codes read as this program: TJ0113.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.